An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome (ELARA)

This open-label study (OV101-18-002) will evaluate the long-term (52 weeks) safety of OV101 in subjects with AS and provide additional OV101 treatment to those subjects who completed Study OV101-15-001 (NCT02996305). Subjects with AS who completed the pharmacokinetic Study OV101-16-001 (NCT03109756) will also be permitted to participate, provided they meet all entry criteria.

Study Overview

• Status: Terminated
• Conditions: Angelman Syndrome
• Intervention / Treatment: Drug: OV101

Detailed Description

This will be an open-label, long-term safety study for evaluation of further treatment with OV101 in subjects with AS who have completed previous Ovid studies (OV101-15-001 or OV101-16-001). There will be no placebo treatment. As this study will enroll subjects who have completed previous AS studies for different periods of time before entering this study, subjects will be required to complete screening and baseline visits before receiving OV101 under this protocol.The secondary objective of this study is to evaluate the long-term efficacy of OV101 treatment assessed by changes in behavior, sleep, and functioning in individuals with AS.

• Study Type: Interventional
• Enrollment (Actual): 141
• Phase: Phase 3

Contacts and Locations

Study Locations

• Israel
  • Ramat Gan, Israel, 52621
    • Ovid Therapeutics Investigative Site
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85006
      • Ovid Therapeutics Investigative Site
  • California
    • San Diego, California, United States, 32123
      • Ovid Therapeutics Investigative Site
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Ovid Therapeutics Investigative Site
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Ovid Therapeutics Investigative Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Ovid Therapeutics Investigative Site
    • Lexington, Massachusetts, United States, 02421
      • Ovid Therapeutics Investigative Site
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • Ovid Therapeutics Investigative Site
  • Pennsylvania
    • Media, Pennsylvania, United States, 19063
      • Ovid Therapeutics Investigative Site
  • Tennessee
    • Nashville, Tennessee, United States, 37212
      • Ovid Therapeutics Investigative Site
  • Washington
    • Tacoma, Washington, United States, 98405
      • Ovid Therapeutics Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years to 49 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Each subject must meet all the following criteria to be enrolled in this study:

1. Has completed the OV101-15-001 or OV101-16-001 study up to the EOS.
2. Is male or female and 13 to 49 years old (inclusive) at the time of inclusion in the OV101-15-001 or OV101-16-001 study.
3. Has a previous diagnosis of AS with molecular confirmation from the OV101-15-001 or OV101-16-001 study.
4. Has an LAR/caregiver capable of providing informed consent and able to attend all scheduled study visits, oversee the administration of study drug, and provide feedback regarding the subject's symptoms and performance as described in the protocol.
5. Provides assent to the protocol (to the extent possible and in accordance with local institutional review board (IRB) and regulatory requirements) and has an LAR/caregiver who will provide written informed consent. Subjects providing assent must do so at the same visit as LAR/caregiver written informed consent is provided.
6. Can swallow study drug capsules or ingest the contents of study drug capsules after sprinkling the capsule contents onto 1 spoon of applesauce or low-fat yogurt.
7. Is currently receiving a stable dose of concomitant medications such as anti-epileptic medication, gabapentin, clonidine, trazadone, melatonin, and special diets for at least 4 weeks prior to Baseline.
8. Agrees to remain sexually abstinent from the first day of screening until 30 days after the last dose of study treatment.
9. Has LAR/caregiver(s) who agree not to post any of the subject's personal medical data or information related to the study on any website or social media site (eg, Facebook, Instagram, Twitter) until notified that the study is completed.

Exclusion Criteria:

Subjects meeting any of the following criteria will be excluded from the study:

1. Discontinued from the OV101-15-001 or OV101-16-001 study due to safety reasons causally related to OV101.
2. Has a concomitant disease (eg, gastrointestinal, renal, hepatic, endocrine, respiratory, or cardiovascular system disease) or condition or any clinically significant finding at Screening that could interfere with the conduct of the study or that would pose an unacceptable risk to the subject in this study.
3. Has poorly controlled seizures defined as > 3 seizures lasting < 3 minutes per week or > 1 seizure episode lasting more than 3 minutes per week or as per medical monitor judgment.
4. Has clinically significant clinical laboratory abnormalities or vital signs at the time of screening (eg, alanine aminotransferase or aspartate aminotransferase > 2.5 × upper limit of normal; total bilirubin or creatinine > 1.5 × upper limit of normal). Retesting of clinical laboratory parameters may be allowed after consultation with the medical monitor or designee.
5. Current use of benzodiazepines, zolpidem, zaleplon, zopiclone, eszopiclone, barbiturates, or ramelteon for sleep within the 4 weeks prior to Day 1. Benzodiazepines administered for situational anxiety related to occasional procedures or events are permitted.
6. Has a history of suicidal behavior or is considered by the investigator to be at increased risk of suicide.
7. Has any condition or circumstance that, in the opinion of the investigator, makes the subject unsuitable for enrollment.
8. Has enrolled in any clinical trial or used any investigational agent or device, or has participated in any investigational procedure, within the 30 days before screening or does so concurrently with this study.
9. Is a family member of the investigator or of study site staff.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: OV101; once daily at bedtime (gaboxadol)	Drug: OV101; Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.; Other Names: gaboxadol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Participants Experiencing Adverse Events in Active Treatment Group	Safety assessments related to the primary study objective of evaluating the safety and tolerability of OV101, including serious adverse events (SAEs) and adverse events (AEs) leading to study discontinuation, as assessed by the number of participants who experienced at least one adverse event.	Change from baseline to Week 39

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To Evaluate the Long-term Efficacy of OV101 Treatment as Assessed by Changes in Behavior in Study Participants With AS Who Were at Least 4 Years Old.	The long-term efficacy of OV101 was assessed by changes in irritability using the Aberrant Behavior Checklist - Irritability subscale (ABC-I), part of the broader ABC-Community (ABC-C). The final value reflects change from baseline to early termination at 39 weeks. The ABC-I consists of 15 items measuring behaviors such as aggression, self-injury, temper tantrums, and mood instability. Each item is rated by a caregiver on a 4-point scale: 0 = not at all a problem; 1 = slight problem; 2 = moderately serious; 3 = severe. Scores range from 0 (no symptoms) to 45 (maximum severity). A higher total score indicates greater behavioral disturbance and worse clinical status. The scale provides a standardized means to track symptom changes over time, making it suitable for evaluating treatment efficacy in neurodevelopmental and neuropsychiatric disorders.	change from baseline to 12 wks and baseline to early termination of the study at 39 weeks

Collaborators and Investigators

• Sponsor: Healx AI

Publications and helpful links

General Publications

• Heussler HS. Emerging Therapies and challenges for individuals with Angelman syndrome. Curr Opin Psychiatry. 2021 Mar 1;34(2):123-128. doi: 10.1097/YCO.0000000000000674.

Study record dates

Study Major Dates

• Study Start (Actual): January 31, 2019
• Primary Completion (Actual): June 4, 2021
• Study Completion (Actual): June 30, 2021

Study Registration Dates

• First Submitted: March 18, 2019
• First Submitted That Met QC Criteria: March 18, 2019
• First Posted (Actual): March 20, 2019

Study Record Updates

• Last Update Posted (Actual): July 18, 2025
• Last Update Submitted That Met QC Criteria: July 17, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Imprinting Disorders; Central Nervous System Diseases; Nervous System Diseases; Pathologic Processes; Genetic Diseases, Inborn; Disease; Congenital Abnormalities; Movement Disorders; Abnormalities, Multiple; Chromosome Disorders; Syndrome; Angelman Syndrome; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Sensory System Agents; Analgesics; Neurotransmitter Agents; GABA Agents; Anticonvulsants; GABA Agonists; Gaboxadol
• Other Study ID Numbers: OV101-18-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No